Bangalore based pharmaceutical company Strides Arcolab has revealed that its subsidiary company, Onco Therapies Ltd has received approval from the US Food and Drug Administration to market two generic cancer drugs in the American market.
The company said that it has been given permission to market Injectable Carboplatin in strengths of 10 mg/mL and packaged in 1,000 mg/100 mL pharmacy bulk packages and Oxaliplatin USP in 50-mg and 100-mg single-use vials in the United States.
AdvertisementStating that it will be launching carboplatin in the near future, the company said, "Carboplatin is part of the oncology portfolio licensed to Pfizer in January, 2010, for the US market and is expected to be launched shortly".
P Cancer-afflicted Robin Gibb On the Path to Recovery Zest of Restaurant Day to Finnish Food Culture M
You May Also Like